HuMax®-TF-ADC(Tisotumab Vedotin,靶向组织因子(tissue factor,TF)的抗体药物偶联物)在针对子宫颈癌的初步临床试验中实现了32%的药物反应率:
l Of the 34patients evaluable for response, 11 patients (32 percent) achieved a response. Fiftypercent of patients achieved clinical benefit after 12 weeks.
l Median durationof confirmed responses was 8.3 months. Three responders remained on study.
l The most commonadverse events of any grade were conjunctivitis (50 percent), epistaxis,fatigue and alopecia (47 percent each) and nausea (44 percent).
l The most commongrade 3 or higher adverse events were vomiting (15 percent) and fatigue, nauseaand abdominal pain (9 percent each).
l Ocular events ofany grade occurred in 53 percent of patients, including three percent withgrade 3 or higher.